Clinical Trial Update: Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HG004 for Leber congenital amaurosis due to RPE65 mutations is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Retinal Diseases Caused By Rpe65 Mutations
• Leber Congenital Amaurosis

Drugs mentioned

• HG004

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations | Phase 1, Phase 2 | Status: RECRUITING